MedTrace Logo

CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis

NCT03168256 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2022-06-28

No results posted yet for this study

Summary

This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this study population

Conditions

Interventions

DRUG

CF101 2mg

CF101 tablets, 2mg BID for 16 weeks

DRUG

CF101 3mg

CF101 tablets, 3mg BID for 16 weeks

DRUG

Apremilast 30mg

Apremilast tablets, 30mg BID for 16 weeks

DRUG

Placebo Oral Tablet

Placebo tablets, BID for 16 weeks

Sponsors & Collaborators

  • Can-Fite BioPharma

    lead INDUSTRY

Principal Investigators

  • Michael David, MD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2022-01-06
Completion
2022-04-27
FDA Drug
Yes

Countries

  • Bosnia and Herzegovina
  • Bulgaria
  • Canada
  • Croatia
  • Israel
  • Moldova
  • Poland
  • Romania
  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168256 on ClinicalTrials.gov